The effects and mechanisms of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on metabolic syndrome in the elderly
10.3760/cma.j.issn.0254-9026.2025.09.016
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂及胰高血糖素样肽1受体激动剂对老年代谢综合征的影响及机制
- Author:
Ruixue QIU
1
;
Dingqiong PENG
1
Author Information
1. 北京大学民航临床医学院内分泌科，北京 100123
- Publication Type:Journal Article
- Keywords:
Elderly;
Metabolic syndrome;
Sodium-glucose cotransporter 2 inhibitors;
Glucagon-like peptide-1 receptor agonists
- From:
Chinese Journal of Geriatrics
2025;44(9):1309-1313
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic syndrome (MetS) represents a clinical syndrome composed of a series of risk factors for cardiovascular and cerebrovascular diseases.Emerging evidence highlights the multifaceted therapeutic potential of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established glucose-lowering efficacy, with recent studies demonstrating their remarkable ability to improve multiple metabolic parameters, including blood pressure reduction, weight loss, and cardiorenal function enhancement, suggesting a pivotal role in improving MetS-related risk factors.The elderly population represents a high-risk cohort for metabolic disorders.Nevertheless, conventional medications are associated with problems such as an elevated risk of hypoglycaemia and insufficient protection of multiple vital organs, including the heart and kidneys.This review expounds on the impacts of SGLT-2i and GLP-1RAs on elderly patients with MetS and their potential mechanisms of action, providing reference value for optimizing the management of metabolism-related diseases in the elderly.
